Role of FBXL19-AS1 in hepatocellular carcinoma by lncRNA–miRNA–mRNA network analysis and its diagnostic and prognostic value

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common neoplastic diseases worldwide. Available biomarkers are not sensitive enough for the diagnosis of HCC, seeking new biomarkers of HCC is urgent and challenging. The purpose of this study was to investigate the role of F-box and leucine-rich repeat protein 19-antisense RNA 1 (FBXL19-AS1) through competing endogenous RNA (ceRNA) network and its diagnostic and prognostic value in HCC.Methods: A comprehensive strategy of genomic data mining, bioinformatics and experimental validation was used to evaluate the clinical value of FBXL19-AS1 in the diagnosis and prognosis of HCC and to identify the pathways that FBXL19-AS1 may be involved in.Results: FBXL19-AS1 was up-regulated in HCC, and its high expression was associated with TNM stage and poor prognosis of HCC patients. The combined use of plasma FBXL19-AS1 and alpha-fetoprotein (AFP) could prominently improve the diagnostic validity for HCC. FBXL19-AS1 might participate in regulating HCC related pathways, including hepatitis C, hepatitis B, microRNAs in cancer, cell cycle, viral carcinogenesis, and proteoglycans in cancer through ceRNA network.Conclusions: Our findings indicated that FBXL19-AS1 not only serves as a potential biomarker for HCC diagnosis and prognosis, but it may be functionally carcinogenic.

FLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers

“…A study conducted by Jiang et al has indicated that LncRNA FLVCR1-AS1 may promote proliferation, migration, and invasion of osteosarcoma cells by regulating the Wnt/β-catenin pathway [ 43 ].…”

“…An experimental study conducted by Hao et al illustrated that the LncRNA FBXL19-AS1/miR-342-3p pathway plays a crucial function in the proliferation, migration, and invasion of Huh7 cells treated by flavonoids of Sophorae Fructus [ 42 ]. Furthermore, another study revealed a positive correlation between FBXL19-AS1 TNM stage and poor prognosis of HCC patients, where FBXL19-AS1 acts as a regulation agent, controlling HCC-associated pathways, including cell cycle, microRNAs in cancer, viral carcinogenesis via ceRNA network [ 43 ]. Consequently, this lncRNA may be considered a diagnostic and prognostic biomarker [ 44 ].…”

“…Many studies have revealed that FBXL19-AS1 can regulate the expression of specific miRNAs that play an oncogenic role in various cancers. FBXL19-AS1 causes cancers by acting in different signaling pathways ( Figure 6 ; Table 4 ) [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ].…”

“…The oncogenic role of lncRNA has been described in several cancers, such as hepatocellular cancer and cholangiocarcinoma [ 42 , 43 , 44 , 45 ], gastric cancer [ 46 , 47 ], colorectal cancer [ 48 ], glioma [ 49 ], lung cancer [ 50 , 51 , 52 ], cervical cancer (CC) [ 53 , 54 ], breast cancer [ 55 , 56 , 57 ], osteosarcoma [ 58 ], nasopharyngeal carcinoma (NPC) [ 59 ], and acute myeloid leukemia (AML) [ 60 ].…”

Identify and Validate the Transcriptomic, Functional Network, and Predictive Validity of FBXL19-AS1 in Hepatocellular Carcinoma

“…This manuscript has been released as a pre-print at Research Square, (He DD, Zhang XK, Zhu XY, et al.) ( 58 ).…”